The FDA on Friday revoked the emergency use authorizations (EUAs) of four monoclonal antibodies for COVID-19. The four drugs -- bebtelovimab, sotrovimab, casirivimab/imdevimab (REGN-COV2), and tixagevimab/cilgavimab (Evusheld) -- had been...
Read more